Literature DB >> 6121868

Effects of N-aralkyl substitution of beta-agonists on alpha- and beta-adrenoceptor subtypes: pharmacological studies and binding assays.

N Decker, M C Quennedey, B Rouot, J Schwartz, J Velly.   

Abstract

The pharmacological and binding properties of four beta-adrenomimetic drugs with N-alkyl substitutions (isoprenaline, terbutaline, salbutamol and soterenol) were compared with those of four corresponding drugs with N-aralkyl substitutions (protokylol, ME 506, salmefamol and zinterol). BD-40 A, a very powerful beta 2-agonist with a related chemical structure, was also included in this study. The beta 1- and beta 2-activities of these drugs were determined on guinea-pig atria and trachea, their alpha-adrenolytic activity was measured on rat aorta and their affinities (Ki) for alpha 1- and alpha 2-adrenoceptors on rat cortical membranes were assessed using [3H]prazosin and [3H]yohimbine. In this group of beta-agonists, substitution of the N-alkyl by an N-aralkyl group had a variable effect on the beta 2-selectivity whereas alpha-adrenolytic properties were always enhanced. An increase of the affinities (Ki) for both alpha 1- and alpha 2-adrenoceptors was found but the effect was much more pronounced for alpha 1-adrenoceptors. These results indicated that the alpha-adrenolytic activity observed with the N-aralkyl beta-agonists was selective for alpha 1-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6121868     DOI: 10.1111/j.2042-7158.1982.tb04195.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  11 in total

Review 1.  Basic pharmacology of new long-acting sympathomimetics.

Authors:  C G Löfdahl
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 2.  Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists.

Authors:  A Lindén; K F Rabe; C G Löfdahl
Journal:  Lung       Date:  1996       Impact factor: 2.584

3.  Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects.

Authors:  A R Guhan; S Cooper; J Oborne; S Lewis; J Bennett; A E Tattersfield
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

Review 4.  Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease.

Authors:  D Faulds; L M Hollingshead; K L Goa
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

Review 5.  Long-acting beta 2-agonists. Role in primary care asthma treatment.

Authors:  A D D'Urzo
Journal:  Can Fam Physician       Date:  1997-10       Impact factor: 3.275

6.  Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: differences in maximum relaxant effect and potency but not in functional antagonism.

Authors:  A Lindén; A Bergendal; A Ullman; B E Skoogh; C G Löfdahl
Journal:  Thorax       Date:  1993-05       Impact factor: 9.139

7.  Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma.

Authors:  A Wallin; T Sandström; L Rosenhall; B Melander
Journal:  Thorax       Date:  1993-06       Impact factor: 9.139

8.  Comparison of the chronotropic effect and the cyclic AMP accumulation induced by beta 2-agonists in rat heart cell culture.

Authors:  M Freyss-Beguin; G Griffaton; P Lechat; D Picken; M C Quennedey; B Rouot; J Schwartz
Journal:  Br J Pharmacol       Date:  1983-04       Impact factor: 8.739

9.  Beta-adrenoceptor regulation and functional responses in the guinea-pig following chronic administration of the long-acting beta 2-adrenoceptor agonist formoterol.

Authors:  A R Kompa; P Molenaar; R J Summers
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-06       Impact factor: 3.000

10.  Formoterol, a new long acting beta 2 agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma.

Authors:  A Wallin; B Melander; L Rosenhall; T Sandström; L Wåhlander
Journal:  Thorax       Date:  1990-04       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.